<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896255</url>
  </required_header>
  <id_info>
    <org_study_id>KY2020-911</org_study_id>
    <nct_id>NCT04896255</nct_id>
  </id_info>
  <brief_title>Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B</brief_title>
  <acronym>OASIS</acronym>
  <official_title>Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B: A Prospective, Multicenter, Real-world Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Foundation for Hepatitis Prevention and Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taiyuan No.3 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yunnan Provincial No.1 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjing No.2 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao No.6 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fourth Affiliated Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Beilun District Traditional Chinese Medicine Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi No.5 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taicang No.1 People's hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, real-world study, recruiting patients with chronic&#xD;
      hepatitis B under anti-viral treatment. The recruited participants will receive peginterferon&#xD;
      alpha based regimen or nucleos(t)ide alone. The primary objective of this study is to compare&#xD;
      the long-term outcomes (including hepatocellular carcinoma, decompensated cirrhosis, etc）of&#xD;
      different anti-viral therapies. The secondary objective of this study is to compare the&#xD;
      serological response rates of different anti-viral therapies, evaluate the predictive value&#xD;
      of HBV-related laboratory testings and describe the kinetics of them results during antiviral&#xD;
      treatment. The follow-up time course of this study will be 5 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will be allocated into two cohorts based on the anti-viral treatment decided by&#xD;
      their doctors. If they are going to take peginterferon alpha based regimen, they will be&#xD;
      allocated in interferon cohort. If they are going to take nucleos(t)ide alone, they will be&#xD;
      allocated in nucleos(t)ide cohort. The follow-up plan will be made by their doctors according&#xD;
      to their conditions. No extra intervention or examination will be given in this study. The&#xD;
      primary outcome is end-stage liver diseases including hepatocellular carcinoma and&#xD;
      decompensated cirrhosis, and the rate of hepatocellular carcinoma and decompensated cirrhosis&#xD;
      will be measure at 1 year，2 years，3 years, 4 years and 5 years from baseline. Secondary&#xD;
      events including HBsAg loss, HBeAg conversion, fibrosis progression and fibrosis, which will&#xD;
      be measured at 24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192&#xD;
      weeks, 216 weeks, 240 weeks from baseline, respectively. Results of laboratory testings will&#xD;
      be recorded at each follow-up visit. The primary objective of this study is to compare the&#xD;
      long-term outcomes (including hepatocellular carcinoma, decompensated cirrhosis, etc）of&#xD;
      different anti-viral therapies. The secondary objective of this study is to compare the&#xD;
      serological response rates of different anti-viral therapies, evaluate the predictive value&#xD;
      of HBV-related laboratory testings and describe the kinetics of them results during antiviral&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 10, 2021</start_date>
  <completion_date type="Anticipated">July 25, 2030</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>rate of hepatocellular carcinoma at 1 year from baseline</measure>
    <time_frame>1 year from baseline</time_frame>
    <description>Rate of hepatocellular carcinoma will be evaluated as an end-stage liver disease event at 1 year，2 years，3 years, 4 years and 5 years from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of hepatocellular carcinoma at 3 years from baseline</measure>
    <time_frame>3 years from baseline</time_frame>
    <description>Rate of hepatocellular carcinoma will be evaluated as an end-stage liver disease event at 1 year，2 years，3 years, 4 years and 5 years from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of hepatocellular carcinoma at 3 years from baseline</measure>
    <time_frame>5 years from baseline</time_frame>
    <description>Rate of hepatocellular carcinoma will be evaluated as an end-stage liver disease event at 1 year，2 years，3 years, 4 years and 5 years from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of decompensated cirrhosis at 1 year from baseline</measure>
    <time_frame>1 year from baseline</time_frame>
    <description>Rate of decompensated cirrhosis will be evaluated as an end-stage liver disease event at 1 year，2 years，3 years, 4 years and 5 years from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of decompensated cirrhosis at 3 years from baseline</measure>
    <time_frame>3 years from baseline</time_frame>
    <description>Rate of decompensated cirrhosis will be evaluated as an end-stage liver disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of decompensated cirrhosis at 5 years from baseline</measure>
    <time_frame>5 years from baseline</time_frame>
    <description>Rate of decompensated cirrhosis will be evaluated as an end-stage liver disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of HBsAg loss</measure>
    <time_frame>24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline</time_frame>
    <description>rate of HBsAg loss will be measured as a serological response event at 24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of HBeAg loss</measure>
    <time_frame>24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline</time_frame>
    <description>rate of HBeAg loss will be measured as a serological response event at 24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of HBeAg conversion</measure>
    <time_frame>24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline</time_frame>
    <description>rate of HBeAg conversion will be measured as a serological response event at 24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of fibrosis progression</measure>
    <time_frame>24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline</time_frame>
    <description>rate of fibrosis progression will be measured as a histological response event at 24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of fibrosis regression</measure>
    <time_frame>24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline</time_frame>
    <description>rate of fibrosis regression will be measured as a histological response event at 24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg level</measure>
    <time_frame>24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline</time_frame>
    <description>HBsAg level will be measured at 24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline, respectively, and kinetics will be described based on the results.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>interferon cohort</arm_group_label>
    <description>Patients who are going to take peginterferon alpha based regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nucleos(t)ide cohort</arm_group_label>
    <description>Patients who are going to take nucleos(t)ide alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alpha based regimen</intervention_name>
    <description>peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study</description>
    <arm_group_label>interferon cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nucleos(t)ide</intervention_name>
    <description>peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study</description>
    <arm_group_label>nucleos(t)ide cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with chronic hepatitis B under anti-viral treatment of peginterferon alpha based&#xD;
        regimen or nucleos(t)ide alone.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients with age ≥18; subjects who are over 70 years of age must be&#xD;
             in generally stable health conditions.&#xD;
&#xD;
          -  There should be evidences that HBsAg has been positive for more than 6 months or&#xD;
             HBV-related histological changes.&#xD;
&#xD;
          -  Planned to receive or already receiving anti-viral treatment with nucleos(t)ide&#xD;
             including Entecavir, Tenofovir, and Tenofoviralafenamide. Or planned to receive&#xD;
             peginterferon alpha 2b, either treated or treatment-naive.&#xD;
&#xD;
          -  Agree to participate in the study and sign the patient informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently treatment-related participating clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenhong Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiming Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Feng Sun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiran Zhang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenhong Zhang, Professor</last_name>
    <phone>13801844344</phone>
    <email>zhangwenhong@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Feng Sun, doctor</last_name>
    <phone>15921403893</phone>
    <email>aaronsf1125@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenhong Zhang, Professor</last_name>
      <phone>13801844344</phone>
      <email>zhangwenhong@fudan.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Feng Sun, doctor</last_name>
      <phone>15921403893</phone>
      <email>aaronsf1125@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015 Oct 17;386(10003):1546-55. doi: 10.1016/S0140-6736(15)61412-X. Epub 2015 Jul 28. Review.</citation>
    <PMID>26231459</PMID>
  </reference>
  <reference>
    <citation>Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016 Aug;16(8):509-23. doi: 10.1038/nri.2016.69. Epub 2016 Jul 4. Review.</citation>
    <PMID>27374637</PMID>
  </reference>
  <reference>
    <citation>Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015 Dec;64(12):1972-84. doi: 10.1136/gutjnl-2015-309809. Epub 2015 Jun 5. Review.</citation>
    <PMID>26048673</PMID>
  </reference>
  <reference>
    <citation>Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA. 2018 May 1;319(17):1802-1813. doi: 10.1001/jama.2018.3795. Review. Erratum in: JAMA. 2018 Sep 18;320(11):1202.</citation>
    <PMID>29715359</PMID>
  </reference>
  <reference>
    <citation>Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Clin Liver Dis (Hoboken). 2018 Aug 22;12(1):33-34. doi: 10.1002/cld.728. eCollection 2018 Jul. Review.</citation>
    <PMID>30988907</PMID>
  </reference>
  <reference>
    <citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.</citation>
    <PMID>28427875</PMID>
  </reference>
  <reference>
    <citation>Lim TH, Gane E, Moyes C, Borman B, Cunningham C. HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes. Hepatol Int. 2016 Sep;10(5):829-37. doi: 10.1007/s12072-016-9709-6. Epub 2016 Mar 8.</citation>
    <PMID>26957439</PMID>
  </reference>
  <reference>
    <citation>Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y, Li Y, Liu Y, Liu G, Mao D, Chi X, Tang H, Li X, Xie Y, Chen X, Jiang J, Zhao P, Hou J, Gao Z, Fan H, Ding J, Zhang D, Ren H. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol. 2018 Mar 28;6(1):25-34. doi: 10.14218/JCTH.2017.00072. Epub 2018 Mar 17.</citation>
    <PMID>29577029</PMID>
  </reference>
  <reference>
    <citation>Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014 Oct;61(4):777-84. doi: 10.1016/j.jhep.2014.05.044. Epub 2014 Jun 7.</citation>
    <PMID>24915612</PMID>
  </reference>
  <reference>
    <citation>Mak LY, Wong DK, Pollicino T, Raimondo G, Hollinger FB, Yuen MF. Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance. J Hepatol. 2020 Oct;73(4):952-964. doi: 10.1016/j.jhep.2020.05.042. Epub 2020 Jun 3. Review.</citation>
    <PMID>32504662</PMID>
  </reference>
  <reference>
    <citation>Shiels MS, Engels EA, Yanik EL, McGlynn KA, Pfeiffer RM, O'Brien TR. Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013. Cancer. 2019 Aug 1;125(15):2621-2630. doi: 10.1002/cncr.32129. Epub 2019 Apr 12.</citation>
    <PMID>30980394</PMID>
  </reference>
  <reference>
    <citation>Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. Am J Gastroenterol. 2020 Feb;115(2):271-280. doi: 10.14309/ajg.0000000000000428.</citation>
    <PMID>31634265</PMID>
  </reference>
  <reference>
    <citation>Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol. 2009;44(5):470-5. doi: 10.1007/s00535-009-0024-z. Epub 2009 Mar 25.</citation>
    <PMID>19308310</PMID>
  </reference>
  <reference>
    <citation>Shiffman ML. Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver Int. 2020 Feb;40 Suppl 1:22-26. doi: 10.1111/liv.14359. Review.</citation>
    <PMID>32077612</PMID>
  </reference>
  <reference>
    <citation>Jang JW, Choi JY, Kim YS, Yoo JJ, Woo HY, Choi SK, Jun CH, Lee CH, Sohn JH, Tak WY, Lee YR, Han KH. Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2018 Dec;16(12):1954-1963.e3. doi: 10.1016/j.cgh.2018.04.063. Epub 2018 May 9.</citation>
    <PMID>29753085</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Wen-hong Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

